<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta name="description" content="Learn how CDKL5 AAV9 gene therapy restores protein expression, meet the team, and explore the data guiding our path to first-in-human trials.">
    <title>About Us | CDKL5 Gene Therapy Coalition</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="css/style.css">
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-XXXXXXX-X"></script>
    <script>
        window.dataLayer = window.dataLayer || [];
        function gtag(){dataLayer.push(arguments);} // minimal GA placeholder
        gtag('js', new Date());
        gtag('config', 'UA-XXXXXXX-X');
    </script>
</head>
<body>
    <header>
        <nav class="navbar container" aria-label="Main navigation">
            <a href="index.html" class="logo" aria-label="CDKL5 Gene Therapy home">
                <svg viewBox="0 0 64 64" role="img" aria-hidden="true">
                    <defs>
                        <linearGradient id="helixGradient" x1="0" y1="0" x2="1" y2="1">
                            <stop offset="0%" stop-color="#303F9F" />
                            <stop offset="100%" stop-color="#E57373" />
                        </linearGradient>
                    </defs>
                    <path d="M16 8c16 0 16 48 32 48" stroke="url(#helixGradient)" stroke-width="6" fill="none" stroke-linecap="round" />
                    <path d="M48 8c-16 0-16 48-32 48" stroke="#FFB6A2" stroke-width="6" fill="none" stroke-linecap="round" />
                    <circle cx="16" cy="8" r="4" fill="#303F9F" />
                    <circle cx="48" cy="56" r="4" fill="#E57373" />
                </svg>
                <span>CDKL5 Gene Therapy</span>
            </a>
            <button class="nav-toggle" type="button" data-nav-toggle aria-label="Toggle navigation" aria-controls="primary-navigation" aria-expanded="false">☰</button>
            <ul class="nav-links" id="primary-navigation" data-nav-links>
                <li><a href="index.html">Home</a></li>
                <li><a href="about.html">About</a></li>
                <li><a href="get-involved.html">Get Involved</a></li>
                <li><a href="parents-caregivers.html">Parents &amp; Caregivers</a></li>
                <li><a href="contact.html">Contact</a></li>
            </ul>
        </nav>
    </header>

    <main>
        <div class="container">
            <section class="section fade-in">
                <span class="badge">Root-cause therapy</span>
                <h1>About our CDKL5 AAV9 program</h1>
                <p>We are a coalition of families, clinicians, and drug developers partnering to deliver a one-time gene therapy that addresses the fundamental deficit driving CDKL5 Deficiency Disorder (CDD). By transporting a functional CDKL5 gene directly into neurons, we aim to restore protein expression, stabilize circuitry, and reclaim developmental potential.</p>
            </section>

            <section class="section fade-in" aria-labelledby="mechanism-heading">
                <h2 id="mechanism-heading">How the therapy works</h2>
                <div class="card-grid">
                    <article class="card">
                        <h3>Targeted delivery</h3>
                        <p>The AAV9 capsid has a proven affinity for central nervous system cells. Delivered intracerebroventricularly (i.c.v.), it disperses through cerebrospinal fluid to reach cortex, hippocampus, and deep brain nuclei.[1][5]</p>
                    </article>
                    <article class="card">
                        <h3>Restoring CDKL5 protein</h3>
                        <p>Once in the nucleus, the payload expresses full-length CDKL5 protein to compensate for the endogenous gene disruption. This supports synaptic scaling, dendritic arborization, and seizure suppression.[1][5]</p>
                    </article>
                    <article class="card">
                        <h3>Sustainable expression</h3>
                        <p>Long-term preclinical data indicate durable expression with no integration into genomic DNA, aligning with established AAV safety expectations from approved therapies like Zolgensma® and Luxturna®.[2]</p>
                    </article>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="team-heading">
                <h2 id="team-heading">Leadership team</h2>
                <div class="card-grid">
                    <article class="card">
                        <h3>Dr. Gai Ayalon, Ph.D.</h3>
                        <p><strong>Drug Development Advisor</strong></p>
                        <p>Neuroscientist leading the CDKL5 Research Foundation's gene therapy program through clinical development. Previously led clinical development programs for pediatric neurodevelopmental disorders at Ultragenyx Pharmaceutical.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Nalin Gupta</h3>
                        <p><strong>Clinical Advisor</strong></p>
                        <p>Pediatric neurologist specializing in rare genetic disorders with expertise in clinical trial design and regulatory pathways.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Adam Numis</h3>
                        <p><strong>Clinical Investigator</strong></p>
                        <p>Pediatric neurologist with focus on epilepsy and developmental disorders, contributing to natural history studies and trial protocols.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Heather Olson</h3>
                        <p><strong>Clinical Investigator</strong></p>
                        <p>Pediatric epileptologist at Boston Children's Hospital with extensive experience in CDKL5 Disorder clinical management and research.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Jacinthe Gingras</h3>
                        <p><strong>Preclinical Research Advisor</strong></p>
                        <p>Molecular biologist specializing in gene therapy vector development and CNS delivery mechanisms.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Lauren Black</h3>
                        <p><strong>Clinical Research Coordinator</strong></p>
                        <p>Expert in clinical trial operations and patient advocacy for rare disease populations.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Michael Templin</h3>
                        <p><strong>Scientific Advisor</strong></p>
                        <p>Neuroscientist with expertise in neurological disease models and therapeutic validation.</p>
                    </article>
                    <article class="card">
                        <h3>Tracy Johnson</h3>
                        <p><strong>Program Manager</strong></p>
                        <p>Experienced program manager coordinating cross-functional teams and regulatory submissions for gene therapy programs.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Sangeeta Joshi</h3>
                        <p><strong>Regulatory Affairs Advisor</strong></p>
                        <p>Regulatory strategist guiding IND preparation and FDA interactions for pediatric rare diseases.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Tim Cote</h3>
                        <p><strong>Clinical Development Advisor</strong></p>
                        <p>Clinical development expert with deep experience in orphan drug programs and accelerated pathways.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Paul Herzich</h3>
                        <p><strong>Medical Monitor</strong></p>
                        <p>Pediatric specialist providing medical oversight and safety monitoring for clinical trials.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Kruti Patel</h3>
                        <p><strong>Clinical Operations Lead</strong></p>
                        <p>Clinical operations specialist managing site selection, patient recruitment, and trial logistics.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Lester Suarez</h3>
                        <p><strong>Biostatistics Advisor</strong></p>
                        <p>Biostatistician designing adaptive trial protocols and endpoint analysis for rare disease studies.</p>
                    </article>
                    <article class="card">
                        <h3>Ilya Musavey</h3>
                        <p><strong>Technical Operations</strong></p>
                        <p>Operations specialist managing GMP manufacturing partnerships and supply chain logistics.</p>
                    </article>
                    <article class="card">
                        <h3>Sarah Caffey</h3>
                        <p><strong>Community Engagement Director</strong></p>
                        <p>Leading family outreach, education programs, and patient advocacy initiatives across global CDKL5 community.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Matthew Simon</h3>
                        <p><strong>Translational Medicine Advisor</strong></p>
                        <p>Physician-scientist bridging preclinical research and clinical application for neurological gene therapies.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Vincent Pons</h3>
                        <p><strong>Scientific Advisor</strong></p>
                        <p>Molecular biologist with expertise in AAV vector design and neurodevelopmental disorder mechanisms.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Kristin Loomis</h3>
                        <p><strong>Preclinical Development Lead</strong></p>
                        <p>Leading toxicology studies and IND-enabling pharmacology for AAV9-CDKL5 gene therapy vector.</p>
                    </article>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="data-heading">
                <h2 id="data-heading">Preclinical evidence at a glance</h2>
                <div class="card-grid">
                    <article class="card">
                        <h3>Neuron targeting</h3>
                        <ul class="info-list">
                            <li>i.c.v. dosing transduced ≥50% of neurons in cortex, hippocampus, and thalamus.[1]</li>
                            <li>Improved hindlimb clasping, open-field exploration, and contextual fear conditioning.[5]</li>
                        </ul>
                    </article>
                    <article class="card">
                        <h3>Functional recovery</h3>
                        <ul class="info-list">
                            <li>UX055 restored motor and cognitive function in CDKL5 knockout mouse models.[2]</li>
                            <li>Human induced pluripotent stem cell organoids showed corrected hyperexcitability.[2]</li>
                        </ul>
                    </article>
                    <article class="card">
                        <h3>Safety and biodistribution</h3>
                        <ul class="info-list">
                            <li>Favorable biodistribution compared with intrathecal delivery, reducing peripheral exposure.[5]</li>
                            <li>No vector-related toxicity observed at efficacious doses (3e11–5e11 vg/g brain).[1]</li>
                        </ul>
                    </article>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="milestones-heading">
                <h2 id="milestones-heading">Milestones</h2>
                <ul class="info-list">
                    <li>April 2024: Completed vector design freeze and pre-IND meeting feedback integration.</li>
                    <li>Q4 2024: Launch translational toxicology in partnership with CRO network.</li>
                    <li>Q2 2025: Manufacture GMP batch and finalize release assays.</li>
                    <li>Q2 2026: Target first participant dosing pending $3.5M fundraising goal.</li>
                </ul>
            </section>
        </div>
    </main>

    <footer>
        <div class="container">
            <div class="footer-grid">
                <div>
                    <h3>Donate</h3>
                    <p>Every contribution advances manufacturing runs and safety studies.</p>
                    <a class="btn btn-primary" href="https://checkout.square.site/merchant/ML47GBM1M9YW9/checkout/7O336ARIT4X5SQTAEX5RDSR3?src=qr" target="_blank" rel="noopener">Donate with Square</a>
                    <a class="btn btn-secondary" href="https://www.paypal.com/us/fundraiser/charity/3700987" target="_blank" rel="noopener">Donate with PayPal</a>
                </div>
                <div>
                    <h3>Stay connected</h3>
                    <form action="https://formspree.io/f/your-form-id" method="post">
                        <label for="newsletter-first-name">First name</label>
                        <input id="newsletter-first-name" name="firstName" type="text" autocomplete="given-name" required>
                        <label for="newsletter-last-name">Last name</label>
                        <input id="newsletter-last-name" name="lastName" type="text" autocomplete="family-name" required>
                        <label for="newsletter-email">Email</label>
                        <input id="newsletter-email" name="email" type="email" autocomplete="email" required>
                        <label>
                            <input type="checkbox" name="isParentCaregiver" value="yes">
                            I am a CDKL5 parent/caregiver
                        </label>
                        <button class="btn btn-primary" type="submit">Subscribe</button>
                    </form>
                </div>
                <div>
                    <h3>Connect with us</h3>
                    <p>Follow real-time updates from families and clinicians.</p>
                    <p><a href="https://www.facebook.com/CDKL5foundation/" target="_blank" rel="noopener">Facebook</a></p>
                    <p><a href="https://www.instagram.com/cdkl5southasia?igsh=eW14bmhjZWI0Y3V2" target="_blank" rel="noopener">Instagram</a></p>
                    <div class="progress-wrapper" data-progress-bar>
                        <p><strong data-raised data-raised="200000"></strong> raised of <strong data-goal data-goal="3500000"></strong></p>
                        <div class="progress-track" aria-hidden="true">
                            <div class="progress-bar"></div>
                        </div>
                        <p class="countdown" data-countdown aria-live="polite">Loading countdown…</p>
                    </div>
                </div>
            </div>
            <div class="footer-legal">
                <p>Privacy Policy: We respect your privacy. | Terms of Use: Standard terms apply. | Medical Disclaimer: This site shares research updates and is not medical advice. Donations support 501(c)(3) led programs.</p>
            </div>
        </div>
    </footer>

    <script src="js/script.js" defer></script>
</body>
</html>
